Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Aug 17, 2020 2:53pm
117 Views
Post# 31419158

Spectral Analytics in the news

Spectral Analytics in the newsMANHATTEN, NY, UNITED STATES, August 17, 2020 /EINPresswire.com/ -- Manhattan, New York, August 17, 2020 – New York-based biotech company, Spectral Analytics (“Spectral”), announces the appointment of Christina DiArcangelo to the executive team as the Chief Clinical Research and Development Officer.

“We are thrilled that Christina DiArcangelo has joined our Executive team at Spectral Analytics as the Chief Clinical Research and Development Officer as she will head up our Clinical Research portfolio. Christina has more than two decades in global Biotechnology, Pharmaceutical, Device, Nutraceutical clinical research experience. Additionally, Christina has also been working globally in the Medical Cannabis and CBD clinical research for the past four (4) years. Christina’s breadth of knowledge and ability to execute is a tremendous asset to Spectral Analytics.” explained Steven Adler, Chief Executive Officer of Spectral Analytics.

“I am very excited about joining the Executive team at Spectral Analytics as the Chief Clinical Research and Development Office. There are so many clinical research studies that we are planning as well as the COVID19 clinical study that is soon to commence. I am look forward to helping so many patients will illnesses that are untreated or not managed. Patients come first. I will still remain Chief Executive Officer with Affinity Bio Partners, Affinity Patient Advocacy and AI Health Outcomes.” explained Christina DiArcangelo.


About Spectral Analytics
Spectral Analytics Inc. is a nutraceutical research company with the fundamental premise the phytocannabinoid supplementation of the endocannabinoid system through the use of cannabinoids and other nutraceuticals will improve health. As well as their COVID19 research, Spectral has developed additional research protocols with supporting studies for the following conditions: ADHD, PTSD, Autism, Weight loss and Diabetes, Cancer and IBD and Digestive Disorders.

For additional information, please contact:
Steven Adler
Spectral Analytics, Inc.
110 East End Avenue, #8A
New York, NY 10028
917-612-4752

https://world.einnews.com/pr_news/524192191/spectral-analytics-appoints-christina-diarcangelo-to-chief-clinical-research-and-development-officer?fbclid=IwAR3ZBFqEeljgqCXchn7UW1LZhpSV2INZEFKxRWG0ODvi94lXMeSvz2TeCr0
<< Previous
Bullboard Posts
Next >>